Dr. Reid Waldman is CEO and a board member of Veradermics, a New Haven-based biopharmaceutical company developing treatments for pattern hair loss. A board-certified dermatologist, he founded the company and led it through its initial public offering earlier this year.
Over the past year, Veradermics reported positive trial results for its lead drug candidate, a pill being developed to treat pattern hair loss. The company continued advancing clinical studies in men and women as it moves closer to a potential market launch.
Veradermics also bolstered its finances by raising nearly $767 million through its IPO and follow-on financings, giving the company funding to advance its drug development programs.
Looking ahead, Waldman said he is focused on preparing Veradermics for a potential transition from a clinical-stage biotechnology company to a commercial organization.
What do you value most about living or doing business in Connecticut?
Connecticut’s life sciences community offers a unique blend of top-tier research institutions, highly educated talent and a tightly-knit ecosystem of startups, established companies and policymakers working together.
That collaborative spirit, combined with strong academic roots and access to innovation networks, makes Connecticut a rewarding place to build and grow a business.